LifeStance Health Group (LFST) to Release Quarterly Earnings on Thursday

LifeStance Health Group (NASDAQ:LFST) will be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. LifeStance Health Group has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Thursday, August 8th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $312.30 million during the quarter, compared to the consensus estimate of $305.85 million. LifeStance Health Group had a negative return on equity of 10.51% and a negative net margin of 13.05%. LifeStance Health Group’s revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.13) EPS. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeStance Health Group Price Performance

LifeStance Health Group stock opened at $6.86 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.22 and a quick ratio of 1.22. The company has a market capitalization of $2.62 billion, a PE ratio of -16.80 and a beta of 1.24. LifeStance Health Group has a one year low of $4.64 and a one year high of $9.20. The business has a 50 day simple moving average of $6.84 and a 200 day simple moving average of $6.17.

Wall Street Analyst Weigh In

Several equities analysts recently commented on LFST shares. UBS Group cut their target price on LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating for the company in a research report on Thursday, August 15th. Barclays cut their target price on LifeStance Health Group from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.25.

Insider Activity at LifeStance Health Group

In related news, insider Ann Varanakis sold 5,269 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $6.28, for a total transaction of $33,089.32. Following the completion of the sale, the insider now directly owns 263,007 shares of the company’s stock, valued at $1,651,683.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.60% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.